Intensity Therapeutics Common Stock Alpha and Beta Analysis
| INTS Stock | 0.40 0.01 2.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Intensity Therapeutics Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Intensity Therapeutics over a specified time horizon. Remember, high Intensity Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Intensity Therapeutics' market risk premium analysis include:
Beta 0.0263 | Alpha 4.55 | Risk 50.95 | Sharpe Ratio 0.0942 | Expected Return 4.8 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Intensity | Build AI portfolio with Intensity Stock |
Intensity Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Intensity Therapeutics market risk premium is the additional return an investor will receive from holding Intensity Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Intensity Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Intensity Therapeutics' performance over market.| α | 4.55 | β | 0.03 |
Intensity Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Intensity Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Intensity Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Intensity Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Intensity Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Intensity Therapeutics shares will generate the highest return on investment. By understating and applying Intensity Therapeutics stock market price indicators, traders can identify Intensity Therapeutics position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Hanging Man | ||
| Long Line Candle |
Intensity Therapeutics Return and Market Media
The median price of Intensity Therapeutics for the period between Fri, Oct 10, 2025 and Thu, Jan 8, 2026 is 0.41 with a coefficient of variation of 37.32. The daily time series for the period is distributed with a sample standard deviation of 0.15, arithmetic mean of 0.41, and mean deviation of 0.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lanc... | 10/30/2025 |
2 | Intensity Therapeutics, Inc. Announces Pricing of 4 Million Registered Direct Offering of Common Stock | 10/31/2025 |
3 | Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium | 12/04/2025 |
4 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 12/05/2025 |
5 | Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium | 12/11/2025 |
6 | Acquisition by Talamo Joseph of 14482 shares of Intensity Therapeutics at 0.262 subject to Rule 16b-3 | 12/31/2025 |
About Intensity Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Intensity or other stocks. Alpha measures the amount that position in Intensity Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Payables Turnover | 0.0236 | 0.0224 | Days Of Inventory On Hand | 53.87 | 47.88 |
Intensity Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Intensity Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intensity Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Intensity Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Intensity Therapeutics. Please utilize our Beneish M Score to check the likelihood of Intensity Therapeutics' management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Intensity Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.